Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Wellcome Trust has today announced that Dame Kay Davies, Dr Lee’s Professor of Anatomy at the University of Oxford, has been appointed as its Deputy Chairman. Dame Kay, who has been a Governor of the Trust since January 2008, will take up the role on 1 October 2013.

Source: Wellcome Trust

Kay DaviesDame Kay will take over as Deputy Chairman when Professor Peter Rigby, former Chief Executive of the Institute of Cancer Research, completes his three-year term. He has been reappointed to serve as a Governor of the Trust until 2016.

Professor Richard Hynes, of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, has also been reappointed as a Governor for a further three years.

Sir William Castell, Chairman of the Wellcome Trust, said: "Dame Kay is an outstanding scientist with an exceptional understanding not only of basic biomedical research, but also the translation of its insights into new therapies and diagnostics. With her great experience of the Wellcome Trust's extraordinary vision and mission, she is ideally placed to support our new director, Professor Jeremy Farrar, who starts in October.

"I am extremely grateful to Peter Rigby for the important role he has played in developing the Trust's funding portfolio during his term as Deputy Chairman, and I am delighted that both he and Richard Hynes have agreed to serve further terms as Governors."

Dame Kay said: "I am delighted to have the opportunity to contribute to the work of the Wellcome Trust in my new role as Deputy Chairman at such an exciting time both for science and for its application to improve human and animal health. There are many challenges ahead, and I very much look forward to working with my fellow governors and the new Director, Jeremy Farrar.

Links:

Wellcome Trust

Similar stories

MRC HIU appoints new Director

Awards and Appointments General

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

Awards and Appointments General

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards and Appointments General

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

Awards and Appointments General

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards and Appointments General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.